Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors (FR-WB-TT/che)
This study is currently recruiting participants.
Verified by The University of Texas Health Science Center, Houston, December 2008
Sponsored by: The University of Texas Health Science Center, Houston
Information provided by: The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT00178698
  Purpose

Thermal therapy/hyperthermia (heat) can increase cancer kill by chemotherapy treatments. By itself, thermal therapy can also kill cancer cells. Whole-body fever-range thermal therapy can safely treat cancer cells wherever they are throughout the entire body. In this study, we are testing the combination of fever-range heat treatment and chemotherapy to see 1) if it improves cancer response compared to the effect of only chemotherapy drugs in current use, 2) if the thermochemotherapy helps the person's own body fight the cancer cells, and 3) if this treatment is safe and comfortable for the patient. This study does not offer heat treatment alone. Any patient with inoperable or metastatic neuroendocrine cancer (any organ), gastric cancer, or lung cancer, including small cell lung cancer, can be treated with the Phase II protocol therapy; however, the patient will need to undergo selected medical tests to make sure this treatment would be safe for them.


Condition Intervention Phase
Neuroendocrine Cancer
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Gastric Cancer
Other: thermochemotherapy
Drug: Cisplatin, Gemcitabine, Interferon-a
Phase II

MedlinePlus related topics: Cancer Fever Lung Cancer Stomach Cancer
Drug Information available for: Cisplatin Gemcitabine hydrochloride Gemcitabine Interferon alfa-n1 Interferon alfa-2a Interferons
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title: A PHASE II CLINICAL TRIAL OF CISPLATIN + GEMCITABINE HCl (GEM) + LOW-DOSE METRONOMIC INTERFERON-a (IFN-a) COMBINED WITH FEVER-RANGE WHOLE-BODY THERMAL THERAPY (FR-WB-TT) IN PATIENTS WITH METASTATIC/OR LOCALLY ADVANCED MALIGNANCIES

Further study details as provided by The University of Texas Health Science Center, Houston:

Primary Outcome Measures:
  • Tumor Response by RECIST criteria (CR+PR) [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Response Duration [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Toxicity [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Quality of Life [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 36
Study Start Date: July 2002
Estimated Study Completion Date: June 2011
Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1
Thermochemotherapy
Other: thermochemotherapy
cisplatin 60 mg/m2 i.v. over 4 hours on day 1 gemcitabine 600 mg/m2 i.v. over 60 minutes on day 3 interferon-alpha 1 million international units s.c. daily for protocol duration
Drug: Cisplatin, Gemcitabine, Interferon-a
cisplatin 60 mg/m2 i.v. over 4 hours gemcitabine 600 mg/m2 i.v. over 1 hour interferon-alpha 100,000 i.u. s.c.daily fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration
Other: thermochemotherapy
After hydration and anti-emetics, cisplatin 60 mg/m2 i.v. is given over 4 hours on day 1. Also on day 1, begin daily low-dose interferon-alpha 1 million international units s.c. On day 3, 36 hours after cisplatin infusion, induce fever-range whole-body thermal therapy to 40 oC (104 oF) for a duration of 6 hrs. When the target temperature of 40 oC is reached, gemcitabine 600 mg/m2 is administered i.v. over 60 minutes, and the temperature is maintained at plateau for a total of 6 hours. The cycle is repeated at 21 to 28 day intervals.

Detailed Description:

Once accepted for this study, you will need to have a central venous line (CV line or port) inserted if you do not already have one. (The line placement may be done by your own doctor, or we will be happy to help you with this procedure).

The treatment cycle begins with 6 hours of intravenous (IV) hydration followed by an infusion of the anti-cancer drug, Cisplatin. In addition, at the beginning of this treatment, you will begin daily low-dose Interferon-alpha that will continue for the entire duration of your participation in this study. The daily low-dose Interferon-alpha, interrupts the division of cancer cells, kills blood vessels feeding the cancer, and slows tumor growth, and as well boosts the body's immunity against the cancer.

Thirty-six hours after the cisplatin infusion, you will be treated with fever-range thermal therapy (whole-body heat). The fever-range whole-body thermal therapy enhances the effect of chemotherapy drugs against the cancer, and is thought to also boost your own immune response against the cancer. When the core body temperature reaches 104oF (40oC), a 30-minute (IV) infusion of another chemotherapy drug, gemcitabine (Gemzar) is given. Cisplatin, low-dose interferon-alpha and gemcitabine are the only chemotherapy drugs used in this treatment protocol. No other chemotherapy drugs are allowed to be given under this treatment plan.

The fever-range whole-body heat treatment is performed while you are lightly sedated. With this type of sedation, you are awake during the treatment but you are not uncomfortable. This type of sedation method is used to reduce any discomfort of the 6-hour heat treatment procedure yet allows you to talk to the nurses.

Your body temperature is raised to 104oF (40oC) over a period of 60-120 minutes. When your body first reaches the target 104oF, we administer the gemcitabine chemotherapy over 60 minutes and continue to maintain the 104oF body temperature for six hours. At the conclusion of the six hours of thermochemotherapy, you will be cooled off to your normal body temperature, which takes about 30-45 minutes. The entire treatment lasts approximately 8 hours. After the treatment is completed, we will observe you for 2 to 12 hours to make sure you have tolerated the treatment.

You will continue the daily low-dose Interferon-alpha. Additionally, you will be given daily Leukine (sargramostim, GM-CSF) injections beginning 3-5 days after receiving chemotherapy to help support your immune system by helping your body create more white blood cells, which are important in helping your body fight infection.

After treatment, you will need a complete blood count with platelet and differential count each week. These lab studies can be done at your own doctor's office or hospital as long as you make sure that the results are faxed to us. They can also be done in our clinic. We will see you again in approximately three to four weeks and the treatment cycle will be repeated.

We always attempt to perform at least two thermo-chemotherapy cycles. After the second treatment, CT and/or MRI scans are repeated to see if your cancer is smaller. These scans, along with a physical examination and the lab studies, are used to determine if additional heat treatments will be performed. Additional treatments continue based on how well your response to the treatment. There is no limit to the number of heat treatments a patient may have.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Any patient with inoperable or metastatic neuroendocrine tumors (any organ), gastric, cholangiocarcinoma, small-bowel, lung, head & neck, or melanoma may be treated
  • Must not have metastasis to the brain
  • Must be able to achieve positive results on preliminary tests
  • Must have a good ECOG score

Exclusion Criteria:

  • Metastasis to the brain
  • Poor results on preliminary tests
  • Poor ECOG score
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00178698

Contacts
Contact: Joan M Bull, M.D. 713-500-6820 Joan.M.Bull@uth.tmc.edu
Contact: Esperanza N Fernandez 713-500-6774 Esperanza.N.Fernandez@uth.tmc.edu

Locations
United States, Texas
Memorial Hermann Hospital Recruiting
Houston, Texas, United States, 77030
Contact: Joan M Bull, M.D.     713-600-6820     Joan.M.Bull@uth.tmc.edu    
Contact: Esperanza N Fernandez     713-500-6774     Esperanza.N.Fernandez@uth.tmc.edu    
Principal Investigator: Joan M Bull, M.D.            
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
Investigators
Principal Investigator: Joan M Bull, M.D. The University of Texas Health Science Center, Houston
  More Information

Related Info  This link exits the ClinicalTrials.gov site

Responsible Party: The University of Texas Health Science Center, Houston ( Joan M.C Bull, M.D. )
Study ID Numbers: HSC-MS-04-259
Study First Received: September 13, 2005
Last Updated: December 15, 2008
ClinicalTrials.gov Identifier: NCT00178698  
Health Authority: United States: Institutional Review Board

Keywords provided by The University of Texas Health Science Center, Houston:
thermochemotherapy
fever range whole body
cisplatin
gemcitabine
daily low dose interferon alpha

Study placed in the following topic categories:
Thoracic Neoplasms
Carcinoma, Neuroendocrine
Gastrointestinal Diseases
Fever
Stomach Diseases
Cisplatin
Respiratory Tract Diseases
Lung Neoplasms
Stomach Neoplasms
Neoplasms, Germ Cell and Embryonal
Neoplasm Metastasis
Neuroepithelioma
Gemcitabine
Interferon-alpha
Non-small cell lung cancer
Digestive System Neoplasms
Interferons
Stomach cancer
Carcinoma
Neuroendocrine Tumors
Carcinoma, Small Cell
Neuroectodermal Tumors
Digestive System Diseases
Lung Diseases
Gastrointestinal Neoplasms
Interferon Alfa-2a
Adenocarcinoma
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:
Antimetabolites
Respiratory Tract Neoplasms
Anti-Infective Agents
Antimetabolites, Antineoplastic
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Antineoplastic Agents
Neoplasms, Nerve Tissue
Physiological Effects of Drugs
Enzyme Inhibitors
Immunosuppressive Agents
Antiviral Agents
Pharmacologic Actions
Neoplasms
Neoplasms by Site
Radiation-Sensitizing Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on January 14, 2009